NCT01904721

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 244 (actual)
• Sponsor: Allergan · Industry
• Sex: Male
• Age: 18 Years – 49 Years
• Healthy volunteers: Not accepted

Summary

This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).

Conditions

• Alopecia
• Alopecia, Androgenetic
• Baldness

Interventions

Type	Name	Description
DRUG	Bimatoprost Solution 1	Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
DRUG	Bimatoprost Solution 2	Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
DRUG	Bimatoprost Vehicle	Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.

Timeline

• Start date: 2013-08-01
• Primary completion: 2014-09-01
• Completion: 2015-01-01
• First posted: 2013-07-22
• Last updated: 2016-03-22
• Results posted: 2015-12-09

Locations

1 site across 1 country: United States